282 related articles for article (PubMed ID: 37866667)
1. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management.
Srivastava S; Jayaswal N; Kumar S; Sharma PK; Behl T; Khalid A; Mohan S; Najmi A; Zoghebi K; Alhazmi HA
Cell Signal; 2024 Jan; 113():110932. PubMed ID: 37866667
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
Lococo F; Boldrini L; Diepriye CD; Evangelista J; Nero C; Flamini S; Minucci A; De Paolis E; Vita E; Cesario A; Annunziata S; Calcagni ML; Chiappetta M; Cancellieri A; Larici AR; Cicchetti G; Troost EGC; Ádány R; Farré N; Öztürk E; Van Doorne D; Leoncini F; Urbani A; Trisolini R; Bria E; Giordano A; Rindi G; Sala E; Tortora G; Valentini V; Boccia S; Margaritora S; Scambia G
BMC Cancer; 2023 Jun; 23(1):540. PubMed ID: 37312079
[TBL] [Abstract][Full Text] [Related]
3. A proteome-level view of brain tumors for a better understanding of novel diagnosis, prognosis, and therapy.
Pai MGJ; Biswas D; Verma A; Srivastava S
Expert Rev Proteomics; 2023; 20(12):381-395. PubMed ID: 37970632
[TBL] [Abstract][Full Text] [Related]
4. Omics-Based Investigations of Breast Cancer.
Neagu AN; Whitham D; Bruno P; Morrissiey H; Darie CA; Darie CC
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375323
[TBL] [Abstract][Full Text] [Related]
5. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
6. Omics sciences and precision medicine in lung cancer.
Micheletti C; Dhuli K; Donato K; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Bernini A; Fulcheri E; Stuppia L; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):37-45. PubMed ID: 37994747
[TBL] [Abstract][Full Text] [Related]
7. Omics sciences and precision medicine in glioblastoma.
Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Asleh K; Riaz N; Nielsen TO
J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence.
Xu Z; Li W; Dong X; Chen Y; Zhang D; Wang J; Zhou L; He G
Clin Chim Acta; 2024 Jun; 559():119686. PubMed ID: 38663471
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders.
Singh S; Sarma DK; Verma V; Nagpal R; Kumar M
Biochem Biophys Res Commun; 2023 Nov; 682():1-20. PubMed ID: 37788525
[TBL] [Abstract][Full Text] [Related]
11. Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer.
Li J; Li L; You P; Wei Y; Xu B
Semin Cancer Biol; 2023 Jun; 91():35-49. PubMed ID: 36868394
[TBL] [Abstract][Full Text] [Related]
12. Omics sciences and precision medicine in thyroid cancer.
Dhuli K; Medori MC; Donato K; Donato K; Maltese PE; Tanzi B; Tezzele S; Mareso C; Miertus J; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Stuppia L; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):11-20. PubMed ID: 37994744
[TBL] [Abstract][Full Text] [Related]
13. Boosting predictive models and augmenting patient data with relevant genomic and pathway information.
Buosi S; Timilsina M; Torrente M; Provencio M; Fey D; Nováček V
Comput Biol Med; 2024 May; 174():108398. PubMed ID: 38608322
[TBL] [Abstract][Full Text] [Related]
14. Are innovation and new technologies in precision medicine paving a new era in patients centric care?
Seyhan AA; Carini C
J Transl Med; 2019 Apr; 17(1):114. PubMed ID: 30953518
[TBL] [Abstract][Full Text] [Related]
15. Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology.
Piga I; L'Imperio V; Capitoli G; Denti V; Smith A; Magni F; Pagni F
Expert Rev Proteomics; 2023; 20(12):419-437. PubMed ID: 38000782
[TBL] [Abstract][Full Text] [Related]
16. Applications of artificial intelligence multiomics in precision oncology.
Srivastava R
J Cancer Res Clin Oncol; 2023 Jan; 149(1):503-510. PubMed ID: 35796775
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis.
Ahmed Z
Prog Mol Biol Transl Sci; 2022; 190(1):101-125. PubMed ID: 36007996
[TBL] [Abstract][Full Text] [Related]
18. An overview of technologies for MS-based proteomics-centric multi-omics.
Rajczewski AT; Jagtap PD; Griffin TJ
Expert Rev Proteomics; 2022 Mar; 19(3):165-181. PubMed ID: 35466851
[TBL] [Abstract][Full Text] [Related]
19. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial design in the era of precision medicine.
Fountzilas E; Tsimberidou AM; Vo HH; Kurzrock R
Genome Med; 2022 Aug; 14(1):101. PubMed ID: 36045401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
